-
1
-
-
0032704708
-
Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development
-
Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17 (1999) 3631-3652
-
(1999)
J Clin Oncol
, vol.17
, pp. 3631-3652
-
-
Rowinsky, E.K.1
Windle, J.J.2
Von Hoff, D.D.3
-
2
-
-
0033778340
-
Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications
-
Gibbs R.A. Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications. Curr Opin Drug Dis Dev 3 (2000) 585-596
-
(2000)
Curr Opin Drug Dis Dev
, vol.3
, pp. 585-596
-
-
Gibbs, R.A.1
-
3
-
-
0034730625
-
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
-
Ashar H.R., James L., Gray K., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275 (2000) 30451-30457
-
(2000)
J Biol Chem
, vol.275
, pp. 30451-30457
-
-
Ashar, H.R.1
James, L.2
Gray, K.3
-
4
-
-
0032541625
-
Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
-
Lebowitz P.F., and Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17 (1998) 1439-1445
-
(1998)
Oncogene
, vol.17
, pp. 1439-1445
-
-
Lebowitz, P.F.1
Prendergast, G.C.2
-
5
-
-
17144361932
-
Farnesyltransferase inhibitor therapy in acute myelogenous leukemia
-
Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 4 (2005) 77-84
-
(2005)
Curr Hematol Rep
, vol.4
, pp. 77-84
-
-
Gotlib, J.1
-
6
-
-
0036738122
-
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
-
Le Gouill S., Pellat-Deceunynck C., Harousseau J.L., et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16 (2002) 1664-1667
-
(2002)
Leukemia
, vol.16
, pp. 1664-1667
-
-
Le Gouill, S.1
Pellat-Deceunynck, C.2
Harousseau, J.L.3
-
7
-
-
23844505374
-
Farnesyltransferase inhibitors in myelodysplastic syndrome
-
Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4 (2005) 186-190
-
(2005)
Curr Hematol Rep
, vol.4
, pp. 186-190
-
-
Feldman, E.J.1
-
8
-
-
0035383789
-
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
-
Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 (2001) 3361-3369
-
(2001)
Blood
, vol.97
, pp. 3361-3369
-
-
Karp, J.E.1
Lancet, J.E.2
Kaufmann, S.H.3
-
9
-
-
0037372488
-
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
-
Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 (2003) 1692-1697
-
(2003)
Blood
, vol.101
, pp. 1692-1697
-
-
Cortes, J.1
Albitar, M.2
Thomas, D.3
-
10
-
-
11144358447
-
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
-
Alsina M., Fonseca R., Wilson E.F., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 (2004) 3271-3277
-
(2004)
Blood
, vol.103
, pp. 3271-3277
-
-
Alsina, M.1
Fonseca, R.2
Wilson, E.F.3
-
11
-
-
0033578751
-
A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors
-
Del Villar K., Urano J., Guo L., and Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem 274 (1999) 27010-27017
-
(1999)
J Biol Chem
, vol.274
, pp. 27010-27017
-
-
Del Villar, K.1
Urano, J.2
Guo, L.3
Tamanoi, F.4
-
12
-
-
23744461504
-
Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a
-
Zhang B., Groffen J., and Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 106 (2005) 1355-1361
-
(2005)
Blood
, vol.106
, pp. 1355-1361
-
-
Zhang, B.1
Groffen, J.2
Heisterkamp, N.3
-
13
-
-
23044465584
-
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
-
Bruzek L.M., Poynter J.N., Kaufmann S.H., and Adjei A.A. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol 68 (2005) 477-486
-
(2005)
Mol Pharmacol
, vol.68
, pp. 477-486
-
-
Bruzek, L.M.1
Poynter, J.N.2
Kaufmann, S.H.3
Adjei, A.A.4
-
14
-
-
0036284741
-
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line
-
Smith V., Rowlands M.G., Barrie E., Workman P., and Kelland L.R. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8 (2002) 2002-2009
-
(2002)
Clin Cancer Res
, vol.8
, pp. 2002-2009
-
-
Smith, V.1
Rowlands, M.G.2
Barrie, E.3
Workman, P.4
Kelland, L.R.5
-
15
-
-
23844540638
-
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341
-
Buzzeo R., Enkemann S., Nimmanapalli R., et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11 (2005) 6057-6064
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6057-6064
-
-
Buzzeo, R.1
Enkemann, S.2
Nimmanapalli, R.3
-
16
-
-
0025808242
-
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo
-
Lassar A.B., Davis R.L., Wright W.E., et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66 (1991) 305-315
-
(1991)
Cell
, vol.66
, pp. 305-315
-
-
Lassar, A.B.1
Davis, R.L.2
Wright, W.E.3
-
17
-
-
0031002833
-
5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line
-
Nagai T., Harigae H., Furuyama K., et al. 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. J Biochem 121 (1997) 487-495
-
(1997)
J Biochem
, vol.121
, pp. 487-495
-
-
Nagai, T.1
Harigae, H.2
Furuyama, K.3
-
18
-
-
0023277545
-
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
-
Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
-
(1987)
Anal Biochem
, vol.162
, pp. 156-159
-
-
Chomczynski, P.1
Sacchi, N.2
-
19
-
-
19344369441
-
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines
-
Miyoshi T., Nagai T., Ohmine K., et al. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochem Pharmacol 69 (2005) 1585-1594
-
(2005)
Biochem Pharmacol
, vol.69
, pp. 1585-1594
-
-
Miyoshi, T.1
Nagai, T.2
Ohmine, K.3
-
20
-
-
0034254368
-
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
-
Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
-
(2000)
Blood
, vol.96
, pp. 1070-1079
-
-
Mahon, F.X.1
Deininger, M.W.2
Schultheis, B.3
-
21
-
-
0033986790
-
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
-
Jiang K., Coppola D., Crespo N.C., et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20 (2000) 139-148
-
(2000)
Mol Cell Biol
, vol.20
, pp. 139-148
-
-
Jiang, K.1
Coppola, D.2
Crespo, N.C.3
-
22
-
-
0034777538
-
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells
-
Tamanoi F., Gau C.-L., Jiang C., Edamatsu H., and Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 58 (2001) 1636-1649
-
(2001)
Cell Mol Life Sci
, vol.58
, pp. 1636-1649
-
-
Tamanoi, F.1
Gau, C.-L.2
Jiang, C.3
Edamatsu, H.4
Kato-Stankiewicz, J.5
-
23
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
-
24
-
-
2142647335
-
The biology of caveolae: lessons from caveolin knockout mice and implications for human disease
-
Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3 (2003) 445-464
-
(2003)
Mol Interv
, vol.3
, pp. 445-464
-
-
Hnasko, R.1
Lisanti, M.P.2
-
25
-
-
23044449149
-
Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases
-
Shen B., Singh P., Liu R., et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays 27 (2005) 717-729
-
(2005)
Bioessays
, vol.27
, pp. 717-729
-
-
Shen, B.1
Singh, P.2
Liu, R.3
-
26
-
-
0037245474
-
Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2
-
Mukhopadhyay D., Houchen C.W., Kennedy S., Dieckgraefe B.K., and Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 11 (2003) 113-126
-
(2003)
Mol Cell
, vol.11
, pp. 113-126
-
-
Mukhopadhyay, D.1
Houchen, C.W.2
Kennedy, S.3
Dieckgraefe, B.K.4
Anant, S.5
-
27
-
-
0034471496
-
Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
-
Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431-502
-
(2000)
Crit Rev Clin Lab Sci
, vol.37
, pp. 431-502
-
-
Fosslien, E.1
-
28
-
-
33746896137
-
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma
-
Kern M.A., Haugg A.M., Koch A.F., et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66 (2006) 7059-7066
-
(2006)
Cancer Res
, vol.66
, pp. 7059-7066
-
-
Kern, M.A.1
Haugg, A.M.2
Koch, A.F.3
|